Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial
BMC Psychiatry — Askari S, Mokhtari S, Shariat SV, et al. | January 14, 2022
The effectiveness of memantine, a non-competitive N-Methyl-D-aspartate (NMDA) receptor antagonist, as an adjunct therapy to sertraline, a selective serotonin reuptake inhibitor (SSRI), in lowering the severity of obsessive-compulsive disorder symptoms and executive function was investigated.
In this placebo controlled, double-blinded, parallel-group, clinical trial of 12 weeks, a total of 70 patients with OCD were recruited to receive sertraline (100 mg daily initially followed by 200 mg daily after week 4) and either memantine (10 mg twice daily) or placebo.
Overall, findings do not suggest memantine as efficacious an adjunctive agent to sertraline for symptoms in patients with OCD.
The improvement in severity of symptoms of patients with moderate to severe OCD did not differ significantly with augmentation of memantine (10mg/ twice per day) to sertraline.
However, a significant improvement was recorded in the patients of memantine arm in the number of completed categories of Wisconsin Card Sorting Test (WSCT), which was used to examine participant’s executive function , in comparison with the placebo group.
No major adverse effects were observed in any of the groups.
Read the full article on BMC Psychiatry